Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16026437 | 0.79 | ALDH1A1 (0.83) | RAB9ASMN1; SMN2PKMALDH1A1LMNA | |
| SCHEMBL27080814 | 0.79 | SMN1; SMN2 (0.73) | RAB9ASMN1; SMN2PKMALDH1A1LMNA | |
| SCHEMBL12593269 | 0.79 | SMN1; SMN2 (0.68) | RAB9ASMN1; SMN2PKMALDH1A1LMNA | |
| SCHEMBL3330886 | 0.79 | CHRNA4 (0.82) | RAB9ASMN1; SMN2PKMALDH1A1LMNA | |
| SCHEMBL1839628 | 0.78 | SMN1; SMN2 (0.76) | RAB9ASMN1; SMN2PKMALDH1A1LMNA | |
| SCHEMBL10272426 | 0.78 | ALDH1A1 (0.74) | RAB9ASMN1; SMN2PKMALDH1A1LMNA | |
| SCHEMBL3337652 | 0.77 | RAB9A (0.57) | RAB9ASMN1; SMN2PKMALDH1A1LMNA | |
| SCHEMBL3337978 | 0.77 | CHRNB2 (0.59) | RAB9ASMN1; SMN2PKMALDH1A1LMNA | |
| SCHEMBL3336200 | 0.77 | CHRNB2 (0.59) | RAB9ASMN1; SMN2PKMALDH1A1LMNA | |
| SCHEMBL3334577 | 0.77 | CHRNB2 (0.63) | RAB9ASMN1; SMN2PKMALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714018-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20070117859-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-05-24 | — | — | US | disclosed |
| US-7164019-B2 | Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC | ROCHE PALO ALTO LLC (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060014767-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014767-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | RAB9A 1690/4885SMN1; SMN2 4305/4885PKM 3681/4885 |
| US-20070117859-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | RAB9A 1690/4885SMN1; SMN2 4305/4885PKM 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.